A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg TriCor (Fenofibrate) Tablets Under Fasting Conditions.

Trial Profile

A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg TriCor (Fenofibrate) Tablets Under Fasting Conditions.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Fenofibrate; Fenofibric-acid
  • Indications Hypercholesterolaemia; Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Sponsors URL Pharma
  • Most Recent Events

    • 01 Jun 2011 Results published in the Clinical Therapeutics.
    • 26 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top